25 results
Thumbnail

D1.16 - Molecular sensitization profiles in house dust mite allergic patients from Valencian Community

Thumbnail

D1.18 - Comparative Analysis of Nasal Secretions and Serum Biomarkers in House Dust Mite Allergy: Correlation with Symptoms and Skin Prick Test Results

Thumbnail

D1.19 - Contribution of Panallergens to Edible Insect Reactivity in Mite-Sensitized Individuals

Thumbnail

D1.20 - Progesterone-Induced Urticaria: Diagnostic and Therapeutic Approach

Thumbnail

D1.22 - Molecular Allergen Sensitization Patterns in Cat, Dog and Horse Allergies in Children

Thumbnail

D1.23 - Unrestricted Potential: The Role of AMS in Tackling Allergy Labels

Thumbnail

D1.24 - Towards risk assessment of peanut sensitised patients based on statistical modelling of 32,500 IgE-macroarray test results

Thumbnail

D1.25 - Clinical Characteristics of Chronic Urticaria in Adults Under 45 Years Old with Vitamin D Insufficiency

Thumbnail

D1.422 - A service review of the complex COVID-19 vaccination service

Thumbnail

D1.425 - Familial Cold Autoinflammatory Syndrome Post COVID-19 Vaccine: A Case Report

Thumbnail

D1.423 - Listening to Urticaria Patients Through Social Media: Analyzing the Impact of the COVID-19 Pandemic

Thumbnail

D1.424 - Clinical-epidemiological profile of patients with Post-Covid syndrome followed at a medical school outpatient clinic

Thumbnail

D1.426 - Cellular immunity profile in patients with urolithiasis in the presence of post-Covid syndrome

Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience